| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/09/2008 | EP1940453A2 Therapeutic combination of hamlet and a hdac inhibitor to treat cancer |
| 07/09/2008 | EP1940437A2 Compositions and methods for treating bacteria |
| 07/09/2008 | EP1940434A2 Antioxidant and fe2+chelating properties of herbal extracts |
| 07/09/2008 | EP1940420A2 Antimicrobial polymers |
| 07/09/2008 | EP1940419A2 Neuroprotectants |
| 07/09/2008 | EP1940418A1 Sulfatides for treatment of autoimmune disorders |
| 07/09/2008 | EP1940417A2 Method of treating clostridium difficile-associated diarrhea |
| 07/09/2008 | EP1940416A2 Boron-containing porphyrin compounds and their uses |
| 07/09/2008 | EP1940415A1 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3 |
| 07/09/2008 | EP1940414A2 Anti mineralocorticoid therapy of infection |
| 07/09/2008 | EP1940413A1 Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
| 07/09/2008 | EP1940412A2 Novel opioid antagonists |
| 07/09/2008 | EP1940411A2 Macroheterocylic compounds as kinase inhibitors |
| 07/09/2008 | EP1940410A1 Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine |
| 07/09/2008 | EP1940409A1 Novel pharmaceutical combinations for the treatment of respiratory disorders |
| 07/09/2008 | EP1940408A1 ADENOSINE A2a RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS |
| 07/09/2008 | EP1940407A2 N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators |
| 07/09/2008 | EP1940406A2 Potassium channel inhibitors |
| 07/09/2008 | EP1940404A2 Pharmaceutical composition comprising 2,3-disubstituted tropanes for the treatment of disorders of sexual desire |
| 07/09/2008 | EP1940403A2 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients |
| 07/09/2008 | EP1940402A2 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 07/09/2008 | EP1940401A2 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| 07/09/2008 | EP1940400A2 Use of enoxaparin for performing percutaneous coronary intervention |
| 07/09/2008 | EP1940399A2 Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases |
| 07/09/2008 | EP1940398A1 Use of pramipexol for treating moderate to severe restless legs syndrome (rls) |
| 07/09/2008 | EP1940397A2 Methods for treating hypertension |
| 07/09/2008 | EP1940396A1 Anthelmintic formulations |
| 07/09/2008 | EP1940395A2 Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
| 07/09/2008 | EP1940394A2 Chemical compounds |
| 07/09/2008 | EP1940393A2 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 07/09/2008 | EP1940392A2 Combination of the pde4 inhibitor and a tetrahydrobiopterin derivative |
| 07/09/2008 | EP1940391A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 07/09/2008 | EP1940390A2 Antibacterial pyrrols |
| 07/09/2008 | EP1940389A2 Modulation of neurogenesis by pde inhibition |
| 07/09/2008 | EP1940388A2 Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection |
| 07/09/2008 | EP1940387A1 Process for the stereoselective preparation of (-)-halofenate and intermediates thereof |
| 07/09/2008 | EP1940386A2 Wortmannin conjugates and uses thereof |
| 07/09/2008 | EP1940385A1 Pharmaceutical composition having a ruthenium oxalato compound and method of using the same |
| 07/09/2008 | EP1940384A1 Process for the preparation of sour cherry seed extract, use of the extract for the preparation of pharmaceutical compositions and pharmaceutical compositions containing said extract |
| 07/09/2008 | EP1940383A1 Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof |
| 07/09/2008 | EP1940382A2 Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| 07/09/2008 | EP1940381A1 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate |
| 07/09/2008 | EP1940380A2 Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands |
| 07/09/2008 | EP1940379A2 Methods for treatment of hemorrhagic shock and related disorders |
| 07/09/2008 | EP1940378A1 Rxr agonists and antagonists, alone or in combination with ppar ligands, in the treatment of metabolic and cardiovascular diseases |
| 07/09/2008 | EP1940377A2 Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same |
| 07/09/2008 | EP1940376A2 Use of neboglamine in the treatment of toxicodependency |
| 07/09/2008 | EP1940375A1 Bis(thio-hydrazide amide) formulation |
| 07/09/2008 | EP1940374A2 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| 07/09/2008 | EP1940373A2 Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence |
| 07/09/2008 | EP1940372A1 Novel aromatic compounds and their use in medical applications |
| 07/09/2008 | EP1940371A1 Food composition |
| 07/09/2008 | EP1940370A2 Use of an nmda receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity |
| 07/09/2008 | EP1940369A2 Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm |
| 07/09/2008 | EP1940366A1 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| 07/09/2008 | EP1940365A2 Liquid dosage forms having enteric properties of delayed and then sustained release |
| 07/09/2008 | EP1940364A2 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
| 07/09/2008 | EP1940360A1 Dispersible tablets comprising deferasirox |
| 07/09/2008 | EP1940358A2 Pharmaceutical compositions |
| 07/09/2008 | EP1940357A2 Pharmaceutical compositions |
| 07/09/2008 | EP1940355A2 Drug delivery nanocarriers targeted by landscape phage |
| 07/09/2008 | EP1940353A2 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis |
| 07/09/2008 | EP1940296A2 Chemical compounds |
| 07/09/2008 | EP1940251A1 Dietary supplement energy-providing to skeletal muscles and protecting the cardio vascular tract |
| 07/09/2008 | EP1940247A2 Method for stimulating intestinal barrier integrity after non-natural birth |
| 07/09/2008 | EP1940246A1 Preventing diseases in infants delivered via caesarean section |
| 07/09/2008 | EP1940245A1 Method for treating and/or preventing infections in infants delivered via caesarean section |
| 07/09/2008 | EP1940231A2 Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition |
| 07/09/2008 | EP1896581A4 Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| 07/09/2008 | EP1845781B1 Use of compounds derived from pyrimidinetrione as acetyl cholinesterase inhibitors, compositions containing said derivatives, and the uses thereof |
| 07/09/2008 | EP1819704B1 Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase |
| 07/09/2008 | EP1794143B1 Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| 07/09/2008 | EP1789041B1 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors |
| 07/09/2008 | EP1784164A4 Methods for transmembrane treatment and prevention of otitis media |
| 07/09/2008 | EP1768978B1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 07/09/2008 | EP1761520B1 Kinase inhibitors |
| 07/09/2008 | EP1755650B1 A biomolecule-containing suspension formulation of increased stability deliverable via an implantable delivery device |
| 07/09/2008 | EP1753512B1 Tetrahydropyridothiophenes |
| 07/09/2008 | EP1753417A4 Selective androgen receptor modulators and methods of use thereof |
| 07/09/2008 | EP1720825B1 Anthranilic acid derivatives, methods for their preparation and use as dhodh inhibitors |
| 07/09/2008 | EP1715890B1 Ctgf as target for the therapy of microalbuminuria in patients with diabetic nephropathy |
| 07/09/2008 | EP1694320B1 Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
| 07/09/2008 | EP1687305B1 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| 07/09/2008 | EP1684747B1 Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases |
| 07/09/2008 | EP1684730B1 Pharmaceutical composition having a cationic excipient |
| 07/09/2008 | EP1673084B1 1-2' (1,4'-biperidin-1'-yl)-1-(phenyl)-ethylcyclohexanol derivatives as monoamine reuptake modulators for the treatment of vasomotor symptoms |
| 07/09/2008 | EP1667727B1 Polyamine-metal chelator conjugates |
| 07/09/2008 | EP1660062B1 Use of colipase-lipase inhibitors in the preparation of a pharmaceutical composition in order to prevent obesity |
| 07/09/2008 | EP1653957B1 Piperidine compounds useful as malonyl-coa decarboxylase inhibitors |
| 07/09/2008 | EP1603580B1 Composition for administration of iron for the treatment of restless legs syndrome |
| 07/09/2008 | EP1583762B1 Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists |
| 07/09/2008 | EP1578744B1 Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
| 07/09/2008 | EP1572648B1 3,6-disubstituted azabicyclo (3.1.0)-hexane derivatives as muscarinic receptor antagonists |
| 07/09/2008 | EP1572167B1 Transdermal buprenorphine dosage regimen for analgesia |
| 07/09/2008 | EP1570839B1 Composition for preparation for external use on skin and method of using the same |
| 07/09/2008 | EP1569612B1 Novel topical use of bis-arylimidazo 1,2-a thiolane derivatives |
| 07/09/2008 | EP1560823B1 4-substituted 1-aminocyclohexane derivatives for utilization as orl1-receptor and mu-opiate receptor ligands |
| 07/09/2008 | EP1539136B1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 07/09/2008 | EP1534289B1 Adenosine a2a receptor antagonists for treating restless legs syndrome or nocturnal myoclonus |
| 07/09/2008 | EP1534070A4 Methods for treating fungal infections |